RBC Sees Weak Merck Data As Positive For Gilead
November 10, 2014 at 09:29 AM EST
In a note from RBC Capital analyst Michael Yee, Merck & Co., Inc.'s (NYSE: MRK) weaker-than-expected data for hepatitis C is ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.